Emjard™ M

Empagliflozin and Metformin Hydrochloride
SGLT2 Inhibitors & Biguanide Combination (Antidiabetic Preparations)

Indication:
Emjard™ M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage & Administration:
Starting dose of Emjard™ M should be individualized based on the patient’s current regimen.

Recommended individualized starting dose:
• In patients on Metformin Hydrochloride, switch to this combination containing Empagliflozin 5 mg with a similar total daily dose of Metformin Hydrochloride.
• In patients on Empagliflozin, switch to this combination containing Metformin Hydrochloride 500 mg with a similar total daily dose of Empagliflozin.
• In patients already treated with Empagliflozin and Metformin Hydrochloride separately switch to this combination containing the same total daily doses of each component.

Take this combination twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to Metformin. The maximum recommended dose is 12.5 mg Empagliflozin/1000 mg Metformin twice daily.

Do not initiate or continue Emjard™ M if creatinine levels > 1.5 mg/dL (males), > 1.4 mg/dL (females), or if eGFR is below 45 mL/min/1.73 m2

Preparation:
Emjard™ M 5/500 Tablet: Each box contains 18 tablets in blister pack.



  • Products By Trade Name

  • Products By Generic

  • Products By Therapeutic Class

  • Herbal & Nutraceuticals

  • AgroVet & Pesticides